The purpose of the study is to compare the effectiveness and safety of the two treatments in reducing the need for red blood cell transfusions. Participants are randomly assigned to receive either elritercept or epoetin alfa and will be treated for up to 24 weeks. During this time, they will have regular clinic visits where blood samples are taken to check hemoglobin levels, which indicate how well the blood is carrying oxygen, and doctors will record whether transfusions are still needed.

The study involves a series of visits scheduled roughly every few weeks. At each visit, a healthcare professional will administer the injection, perform a quick blood test, and ask about any side effects. The overall goal is to see if participants can stay without transfusions for a sustained period while their hemoglobin improves.

The purpose of this study is to see if luspatercept can help improve the production of red blood cells in patients with these rare blood disorders. Specifically, the study wants to find out if the treatment can reduce the need for blood transfusions or increase the level of hemoglobin, which is the protein in red blood cells that carries oxygen throughout the body. The study will measure whether patients need fewer transfusions or have higher hemoglobin levels after receiving the treatment.

During the study, patients will receive luspatercept injections over a period of up to 52 weeks. The study will check how well the treatment works by looking at changes in transfusion needs and hemoglobin levels at different time points, including at 12 weeks, 24 weeks, and 48 weeks. Patients will have regular blood tests and pregnancy tests if applicable, and will be monitored for any effects of the treatment throughout the study period and for some time after treatment ends.

The purpose of the study is to evaluate how effective elritercept is in reducing the number of red blood cell transfusions needed by participants. The study will involve participants receiving either the treatment or a placebo, and their progress will be monitored over a period of time. The main goal is to see if participants can achieve transfusion independence, meaning they do not need transfusions for at least eight weeks during the study period.

Participants will be closely monitored for any side effects or changes in their health, including laboratory tests, vital signs, and heart function tests. The study aims to provide valuable information on the safety and effectiveness of elritercept for treating transfusion-dependent anemia in people with myelodysplastic syndromes.

Participants in the study will be randomly assigned to receive either Mitapivat or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, during which participants will take the medication orally in the form of tablets.

The main goal is to see if Mitapivat can improve anemia by increasing hemoglobin levels, which is a protein in red blood cells that carries oxygen. Additionally, the study will look at how Mitapivat affects the frequency of sickle cell pain crises. Participants will be monitored regularly to assess any changes in their condition and to ensure their safety throughout the study. The results will help determine if Mitapivat is a beneficial treatment option for people with Sickle Cell Disease.

The study is divided into different parts. Initially, participants will receive increasing doses of KER-050 to determine the safest and most effective dose. This phase will help understand how well participants tolerate the treatment. In the next phase, the study will expand to include more participants to further assess the safety of the chosen dose. There is also a long-term extension part of the study to evaluate the ongoing safety of KER-050, with or without Ruxolitinib, over a longer period.

Participants in the study will receive either KER-050 alone or in combination with Ruxolitinib. The study will monitor the participants for any side effects and measure how the treatments affect their condition. The study aims to find out if these treatments can help manage Myelofibrosis symptoms, improve blood cell counts, and reduce the need for blood transfusions. The study will also look at changes in spleen size using imaging techniques like CT or MRI. The trial is expected to continue until 2029, providing valuable information on the long-term effects of these treatments.

The purpose of the study is to evaluate the safety and tolerability of different doses of elritercept. The study is divided into two main parts. In the first part, participants will receive increasing doses of elritercept to determine the most suitable dose for further testing. In the second part, the selected dose will be confirmed for its safety and tolerability. There is also a long-term extension phase to assess the long-term safety of elritercept in these patients.

Participants in the study will receive elritercept through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants for any side effects and how well they tolerate the treatment. The trial aims to find out if elritercept can help reduce the need for blood transfusions and improve the overall blood cell production in patients with MDS. The study will also look at how the treatment affects the progression of the disease over time.

The purpose of this study is to evaluate the long-term safety of luspatercept, including monitoring for any progression to more serious conditions such as acute myeloid leukemia (AML) or the development of other types of cancer. Participants in this study will receive luspatercept as a solution for injection, which is administered under the skin. The study is designed as an open-label, single-arm, rollover study, meaning all participants will receive the treatment without a comparison group receiving a placebo.

Throughout the study, participants will be monitored for any adverse events or changes in their condition. The study will also track overall survival and any new growths that may develop. The maximum treatment period for participants is up to 360 days, during which they will continue to receive the treatment and be regularly assessed by healthcare professionals. This study aims to provide valuable information on the long-term effects and safety of luspatercept for individuals with these blood disorders.

The purpose of the study is to see if giving 1000 mg of Ferric Carboxymaltose immediately after certain types of surgeries, such as liver or pancreatic surgery, or complex aortic surgery, can improve recovery. These surgeries often involve significant blood loss, which can lead to severe anemia. The study will look at various outcomes, including the number of blood transfusions needed, the severity of anemia after surgery, and changes in quality of life five weeks after surgery. Participants will be randomly assigned to receive either the Ferric Carboxymaltose treatment or a placebo.

The study will follow participants for up to five years to observe the long-term effects of the treatment. Researchers will assess whether the treatment affects recovery, the rate of complications after surgery, and the ability to receive further cancer treatments if needed. They will also monitor for any side effects during the treatment and the follow-up period. The goal is to determine if this iron treatment can help improve outcomes for patients undergoing major surgeries with significant blood loss.

The main goal of this research is to see if this intravenous iron treatment can reduce the need for blood transfusions in patients with anemia ahead of their planned surgery for revascularization. Revascularization is a procedure used to improve blood flow to the lower limbs. By providing this iron treatment before surgery, the study aims to reduce complications associated with anemia and improve recovery outcomes.

Participants in this study include adults with anemia and chronic lower limb ischemia who are scheduled to undergo surgical procedures to restore blood flow. Throughout the study, researchers will be measuring various factors related to hemoglobin levels, which are crucial for transporting oxygen in the blood, as well as observing how this treatment may affect the length of hospital stays and the patients’ overall recovery and quality of life after the surgery.

The purpose of the study is to evaluate how well RVU120 can help improve anemia in patients with lower-risk MDS. Participants in the study will receive the medication over a period of time, and their response to the treatment will be monitored. The study will look at how the drug affects the production of red blood cells and whether it can reduce the need for blood transfusions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of RVU120.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to gather information on the safety and effectiveness of RVU120 in treating anemia associated with MDS. This research could potentially lead to new treatment options for patients with this condition.

The purpose of the study is to assess how well canakinumab works and how safe it is for patients with these conditions. Participants in the study will receive canakinumab over a period of time, and their response to the treatment will be monitored. The study will look at whether there is an improvement in hemoglobin levels, which is a measure of red blood cells in the blood, and whether this improvement lasts for at least eight weeks. The study will also observe if patients can avoid needing blood transfusions during this time.

This trial is open-label, meaning both the researchers and participants know that canakinumab is being administered. The study is designed to gather information on the effectiveness of canakinumab in treating anemia associated with lower-risk MDS or MDS/MPN, providing valuable insights into potential new treatment options for these conditions.

The purpose of the study is to explore how effective and safe AG-946 is for people with anemia due to LR-MDS. The study is divided into two phases. In the first phase, researchers aim to see if the treatment shows promise in helping patients. In the second phase, they will look at whether the treatment can help patients become independent of blood transfusions, meaning they won’t need transfusions for a certain period. Participants will take the medication for a maximum of 180 days, and their health will be monitored throughout the study.

Some participants will receive the actual medication, while others may receive a placebo. The study will help determine if AG-946 can improve the condition of those with LR-MDS by increasing their hemoglobin levels, which is a protein in red blood cells that carries oxygen. The trial will also assess any side effects or changes in the participants’ health during the study period. This research is important for finding new ways to manage anemia in people with LR-MDS.